alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
No. 68386.

protests 63/11410, etc. (Los Angeles).

#### Draper Tag & Label Company et al. *v.*United States,

*299Opinion by

Eobd, J.

In accordance with stipulation of counsel that the merchandise consists of rayon labels similar in all material respects to those the subject of *Bruce Duncan Co., Inc., a/c Standard Commodities Import & Mosport Corp.*v. *United States*(51 Cust. Ct. 27, C.D. 2409), the claim of the plaintiffs was sustained.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Diabetes and Digestive and Kidney Diseases Initial Review Group; Diabetes, Endocrinology and Metabolic Diseases B Study Section Diabetes, Endocrinology and Metabolic Diseases B Study Section.                    

*Date:*                         October 25-27, 2023.                    

*Time:*                         10:00 a.m. to 3:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, NIDDK Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Charlene J. Repique, Ph.D., Scientific Review Officer, NIDDK/Scientific Review Branch, National Institutes of Health, 6707 Democracy Blvd., Room 7013, Bethesda, MD 20892, (301) 594-7791,                         *charlene.repique@nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: September 20, 2023.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-20753 Filed 9-25-23; 8:45 am]

BILLING CODE 4140-01-P
Case No. 12,884.

#### SIMPSON v. LEIPER.

Circuit Court, E. D. Pennsylvania.

May, 1848.

Damages — Verdict—What Excluded.

Expenses and counsel fees are not to be included in the verdict as actual damages.

Before GRIER, Circuit Justice.

[Cited in 2 Whart. Dig. 414, to the point as stated above. Nowhere reported; opinion not now accessible.)
From: tsruss@fairpoint.net

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 2:02:03 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

Sheila Russell

Augusta, ME 04330
Exhibit 32.2



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002



Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
and in connection with the Quarterly Report on Form 10-Q of Collins & Aikman Floorcoverings, Inc. (the Corporation) for the quarterly period ended April 30, 2005, as filed with the Securities and Exchange Commission on the date
hereof (the Report), the undersigned, the Chief Financial Officer of the Corporation, certifies that:



|(3) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|--- | ---------------------------------------------------------------------------------------------------------------------



|(4) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Corporation.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------



/s/ Leonard F. FerroLeonard F. FerroVice President and Chief Financial Officer
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                             250
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               150,250
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 150,250
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            45
<OTHER-SE>                                     150,205
<TOTAL-LIABILITY-AND-EQUITY>                   150,250
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        


</TABLE>
No. 64503.

#### Schenley Distilleries, Inc., et al. *v.*United States,

protests 116656-K, etc. (San Francisco).

Opinion by

Richardson, J.

In accordance with stipulation of counsel that the merchandise and issues are similar in all material respects to those involved in *United States*v. *R. C., Williams & Co., Inc.*(40 C.C.P.A. 130, C.A.D. 508), and *Austin, Nichols & Co., Inc.*v. *United, States*(22 Cust. Ct. 33, C.D. 1155), the claim of the plaintiffs was sustained.
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsA Comparison of Three Methods for Measuring Distortion in Optical WindowsIt's important that imagery seen through large-area windows, such as those used on space vehicles, not be substantially distorted. Many approaches are described in the literature for measuring the distortion of an optical window, but most suffer from either poor resolution or processing difficulties. In this paper a new definition of distortion is presented, allowing accurate measurement using an optical interferometer. This new definition is shown to be equivalent to the definitions provided by the military and the standards organizations. In order to determine the advantages and disadvantages of this new approach, the distortion of an acrylic window is measured using three different methods: image comparison, moiré interferometry, and phase-shifting interferometry.Document ID20160001417Acquisition SourceKennedy Space CenterDocument TypeTechnical Memorandum (TM)AuthorsYoungquist, Robert C.*(NASA Kennedy Space Center Cocoa Beach, FL United States)*Nurge, Mark A.*(NASA Kennedy Space Center Cocoa Beach, FL United States)*Skow, Miles*(NASA Kennedy Space Center Cocoa Beach, FL United States)*Date AcquiredFebruary 2, 2016Publication DateApril 1, 2015Subject CategoryOpticsReport/Patent NumberKSC-E-DAA-TN23489NASA/TM-2015-218822Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.KeywordsInterferometryImage ComparisonDistortionAvailable DownloadsNameType20160001417.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
From: pmercure@comcast.net

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 4:04:08 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

Peter Mercure

, 30144-1561
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

**FORM 8-K**

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 19, 2007

 

 

**FIRST NATIONAL LINCOLN CORPORATION**

(Exact name of Registrant as specified in charter)

 

MAINE

(State or other jurisdiction of incorporation)

 

0-26589 01-0404322

(Commission file number) (IRS employer identification no.)

 

Main Street, Damariscotta, Maine 04853

(Address of principal executive offices) (Zip Code)

 

(207) 563-3195

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is

intended to simultaneously satisfy the filing obligations

of the registrant under any of the following provisions:

 

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

 

 

TABLE OF CONTENTS

 

| Item 8.01 Other Events | Page 1 |
|------------------------|--------|

 

| Item 9.01 Financial Statements and Exhibits. | Page 1 |
|----------------------------------------------|--------|

 

| Signatures | Page 2 |
|------------|--------|

 

| Exhibit Index | Page 3 |
|---------------|--------|

Section 8 - Other Events

 

Item 8.01 Other Events.

 

On September 19, 2007, the Registrant issued the press release filed herewith as Exhibit 99.1 

announcing the declaration of a cash dividend.

 

Section 9 - Financial Statements and Exhibits

 

Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits.

 

(c) Exhibits.

--------

 

The following Exhibits are being furnished herewith:

 

99.1 Registrant's Press Release dated September 19, 2007.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the

Registrant has duly caused this report to be signed on its behalf by the

undersigned hereunto duly authorized.

 

 

FIRST NATIONAL LINCOLN CORPORATION

 

By: /s/ F. STEPHEN WARD

---------------------

F. Stephen Ward

Executive Vice President & 

Chief Financial Officer

 

Dated: September 19, 2007

 

Exhibit Index

-------------

 

Exhibit

Number Description of Exhibit

------ ----------------------

 

99.1 Registrant's Press Release dated September 19, 2007.
Pursuant to 14 C.F.R. Part 11, the following summary is provided for publication in the Federal Register,

should it be determined that publication is needed:
Applicant Pennell Photography Inc. seeks an exemption from the following rules:

14 C.F.R. §21, subpart H; 14 C.F.R 45.23(b);14 C.F.R. §§ 61.113( a) & (b);91.7 (a); 91.9(b) (2);91.103(b);91.109; 91.119; 91.121; 91.151(a);91.203(a) and (b); 91.405 (a); 91.407 (a) (1); 91.409 (a) (2); 91.409 (a) (2) and 91.417 (a) & (b) to operate commercially a small unmanned vehicle (55lbs or less). Approval ofexemptions allowing commercial operations ofsUASs, will enhance safety by reducing risk. Conventional operations, using jet or piston power aircraft, operate at extremely low altitudesjustfeet from the subjects being filmed and in extreme proximity to people and structures and present the risks associated with vehicles that weigh in the neighborhood of4,000lbs, carrying large amounts ofjetA or otherfuel. Such aircraft mustflyto and from the operational location. In contrast, a sUAS weighing fewer than 55 lbs. and powered by batteries eliminates virtually all ofthat risk given the reduced mass and lack ofcombustible fuel carried on board. The sUAS is carried to the operation site and not flown. The sUAS will carry no passengers or crew and, therefore, will not expose them to the risks associated with manned aircraftflights. The operation ofsmall UASs, weighting less than 55 lbs., conducted in the strict conditions outlined above, will provide an equivalent level ofsafety supporting the grant ofthe exemptions requested herein, including exempting the applicant from the requirements of Part 21 and allowing commercial operations. These lightweight aircraft operate at slow speeds, close to the ground, and in a sterile environment and, as a result, are far saferthan conventional operations conducted with turbine helicopters operating in close proximityto the ground and people.
[Federal Register Volume 88, Number 187 (Thursday, September 28, 2023)]
[Notices]
[Pages 66858-66859]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21145]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Heart, Lung, and Blood Initial Review Group; 
NHLBI

[[Page 66859]]

Institutional Training Mechanism Study Section.
    Date: December 1, 2023.
    Time: 10:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge I, 6705 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Michael P. Reilly, Ph.D., Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute, 6705 Rockledge Drive, Room 208-Z, Bethesda, MD 
20892, 301-827-7975, <a href="/cdn-cgi/l/email-protection#93e1f6faffffeafee3d3fdfbfff1fabdfdfafbbdf4fce5"><span class="__cf_email__" data-cfemail="a5d7c0ccc9c9dcc8d5e5cbcdc9c7cc8bcbcccd8bc2cad3">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: September 22, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-21145 Filed 9-27-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit 4(i)


Amendment No. 1 to
the Sub-Advisory Agreement


This Amendment dated as of [_______], 2012
is entered into by and between BlackRock Advisors, LLC, a Delaware limited liability company (the “Adviser”), and BlackRock
Financial Management, Inc., a Delaware corporation (the “Sub-Adviser”).


WHEREAS, the Adviser and the Sub-Advisor
have entered into a Sub-Investment Advisory Agreement dated September 29, 2006 (the “Sub-Advisory Agreement”) pursuant
to which the Adviser appointed the Sub-Adviser to act as sub-adviser with respect to BlackRock Managed Volatility V.I. Fund (formerly,
BlackRock Balanced Capital V.I. Fund) (the “Fund”), a series of BlackRock Variable Funds, Inc. (the “Corporation”);
and


WHEREAS, the Sub-Advisory Agreement provides
that the Adviser will pay to the Sub-Adviser a monthly fee in arrears at an annual rate equal to the amount set forth in Schedule
A thereto; and


WHEREAS, the Sub-Advisory Agreement provides
that the Sub-Advisory Agreement may be amended by the parties only if such amendment is specifically approved by the vote of the
Board of Directors of the Corporation, including a majority of those Directors who are not parties to the Sub-Advisory Agreement
or interested persons of any such party cast in person at a meeting called for the purpose of voting on such approval and, where
required by the Investment Company Act of 1940, by a vote of a majority of the outstanding voting securities of the Fund; and


WHEREAS, the Board of Directors of the
Corporation, including a majority of those Directors who are not interested persons, specifically approved this amendment;


NOW, THEREFORE, the parties hereto, intending
to be legally bound, hereby agree as follows:


		1.	Schedule A of the Sub-Advisory Agreement is hereby amended as set forth on the Schedule A attached hereto with respect to the
Fund.



		2.	Except as otherwise set forth herein, the terms and conditions of the Sub-Advisory Agreement shall remain in full force and
effect.



 




    	-1-



    	 



    

IN WITNESS WHEREOF, the parties hereto
have caused this Amendment No. 1 to the Sub-Advisory Agreement to be executed by their officers designated below as of the day
and year first above written.


BLACKROCK ADVISORS, LLC


 


 


 


By:                                                 


Name:


Title:


 


 


 


BLACKROCK FINANCIAL MANAGEMENT, INC.


 


 


 


By:                                                 


Name:


Title:


 


 




    	-2-



    	 



    

 


Schedule A


Pursuant to Section 7 of the Sub-Advisory
Agreement, for that portion of the BlackRock Managed Volatility V.I. Fund for which the Sub-Adviser acts as sub-adviser, the Adviser
shall pay a fee to the Sub-Adviser equal to [_______] percent ([__]%) of the advisory fee received by the Adviser from the Portfolio
with respect to such portion, net of: (i) expense waivers and reimbursements, (ii) expenses relating to distribution and sales
support activities borne by the Adviser, and (iii) administrative, networking, recordkeeping, sub-transfer agency and shareholder
services expenses borne by the Adviser.


 






    	-3-